GlassScriptPhysician profile
Carol Vincent
NPI 1295341170
$3,514.45
in general payments reported to CMS, 2019-2025
28 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $67.19 · 2023: $419 · 2024: $1,151 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,447.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $496.74 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $450.44 | 2023-2025 | Ozempic, Rybelsus, Tresiba |
| Amgen INC. | $340.27 | 2024-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $330.54 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $250.85 | 2023-2024 | |
| Lilly USA, LLC | $220.08 | 2023-2025 | Jardiance, Mounjaro, Kisunla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $216.98 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $184.37 | 2025 | Voquezna |
| Intuitive Surgical, INC. | $121.15 | 2024 | |
| Merck Sharp & Dohme LLC | $108.23 | 2023-2025 | Gardasil 9, Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.33 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Exact Sciences Corporation | $82.75 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $80.55 | 2024-2025 | |
| Theratechnologies INC. | $67.19 | 2022 | |
| Glaxosmithkline, LLC. | $59.66 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $50.92 | 2024 | Korlym |
| Esperion Therapeutics, INC. | $47.84 | 2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $42.81 | 2023-2024 | Gvoke Hypopen |
| Radius Health, INC. | $41.66 | 2024 | Tymlos |
| Eisai INC. | $39.60 | 2024-2025 | |
| Abbott Laboratories | $39.20 | 2024 | Freestyle Libre 3 |
| Regeneron Healthcare Solutions, INC. | $29.41 | 2023 | Evkeeza |
| Janssen Pharmaceuticals, INC | $28.52 | 2024 | Xarelto |
| Medtronic, INC. | $27.41 | 2025 | Propel |
| Vivus LLC | $20.46 | 2023 | Qsymia |
| Scpharmaceuticals INC. | $19.07 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.22 | 2024 | |
| Shield Therapeutics INC | $16.20 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carol Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.